Business US
Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform – Johnson & Johnson
- Johnson & Johnson to Acquire Firefly Bio, Inc. to Expand Oncology Pipeline with Novel Degrader Antibody Conjugate Platform Johnson & Johnson
- Johnson & Johnson to Buy Firefly Bio for $1 Billion WSJ
- J&J spends $1 billion to enter KRAS race for cancer treatments statnews.com
- J&J makes $1B bet on emerging DAC space by netting Firefly Bio Fierce Biotech
- J&J to buy cancer drug technology developer Firefly Bio for $1 billion Reuters
